Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DMSA Treatment for Autism and Heavy Metal Toxicity
NCT00811083Phase 2Completed
- Sponsor
- Sonoran University of Health Sciences
- Start
- May 2005
- Primary completion
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of succimer in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Sonoran University of Health Sciences. Primary endpoints: Effect of DMSA therapy on the symptoms of autism at 4 months and Safety of DMSA therapy at 4 months. Started May 2005; status: completed.
02
Drugs
succimer
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT00811083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00811083.